Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Check Point Software Technologies Ltd (CHKP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Check Point Software Technologies Ltd — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Check Point Software Technologies Ltd trades at $132 (market cap $13.70B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.9× Check Point Software Technologies Ltd's market cap. Which is the better fit depends on your goals.
| ALNY | CHKP | |
|---|---|---|
Market Cap | $39.89B | $13.70B |
Sector | Health | Technology |
52-Week High | $491.22 | $223.00 |
52-Week Low | $278.09 | $112.47 |
Enterprise Value | $38.15B | $12.91B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Check Point Software (CHKP) trades at $131.70, down 4.68% today, amid a mixed technical picture with a bullish moving average signal but overbought RSI readings. The company maintains strong fundamentals with a 38.37% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights strategic AI partnerships with OpenAI and AWS, positioning it for growth in cybersecurity.
The outlook is cautiously optimistic with a consensus price target of $148.73 offering 13% upside. Risks include competitive pressures and a potential slowdown in software spending. Analyst sentiment is balanced with 46% buy ratings, though insider selling and an ongoing legal investigation warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Check Point Software Technologies Ltd
Check Point is a global leader in cybersecurity solutions. It provides comprehensive protection against advanced cyber threats for corporate networks, cloud environments, mobile devices, and critical infrastructure.
Read more on CHKP →
